Removal of aprotinin from low-dose aprotininytranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery

Interactive Cardiovascular and Thoracic Surgery

Volumn 12, Issue 2, 2011, Pages 135-140

  Vonk, Alexander B A ^a   Meesters, Michael I ^a   Schats, Joep ^a   Romijn, Johannes W A ^a   Jansen, Evert K ^a   Boer, Christa ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bleeding; Hemostasis; Hyperfibrinolysis; Low dose aprotinin; Transfusion

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; CEFAZOLIN; DEXAMETHASONE; FRESH FROZEN PLASMA; LORAZEPAM; TRANEXAMIC ACID;

AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BODY MASS; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MORTALITY; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; THERMODILUTION; THORAX SURGERY;

AGED; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD COAGULATION; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOSTATICS; HUMANS; MALE; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 79551588601     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1510/icvts.2010.250936     Document Type: Article

References (15)

1. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperativeallogeneic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886.
2. Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L. Hemostaticefficacy of dipyridamole, tranexamic acid, and aprotinin in coronarybypass grafting. Ann Thorac Surg 1995;59:438-442.
3. Bernet F, Carrel T, Marbet G, Skarvan K, Stulz P. Reduction of bloodloss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin-treatedpatients. J Card Surg 1999;14:92-97.
4. Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R. Tranexamic acid and aprotinin in primary cardiac operations: ananalysis of 220 cardiac surgical patients treated with tranexamic acidor aprotinin. Anesth Analg 2008;107:1469-1478.
5. McEvoy MD, Reeves ST, Reves JG, Spinale FG. Aprotinin in cardiacsurgery: a review of conventional and novel mechanisms of action. Anesth Analg 2007;105:949-962.
6. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J; Investigatorsof the Multicenter Study of Perioperative Ischemia Research Group;Ischemia Research and Education Foundation. Mortality associated withaprotinin during 5 years following coronary artery bypass graft surgery. J Am Med Assoc 2007;297:471-479.
7. Speekenbrink RG, Wildevuur CR, Sturk A, Eijsman L. Low-dose and highdoseaprotinin improve hemostasis in coronary operations. J ThoracCardiovasc Surg 1996;112:523-530.
8. Misfeld M, Dubbert S, Eleftheriadis S, Siemens HJ, Wagner T, Sievers HH. Fibrinolysis-adjusted perioperative low-dose aprotinin reducesblood loss in bypass operations. Ann Thorac Surg 1998;66:792-799.
9. Waldow T, Krutzsch D, Wils M, Plötze K, Matschke K. Low-dose aprotininand low-dose tranexamic acid in elective cardiac surgery with cardiopulmonarybypass. Clin Hemorheol Microcirc 2009;42:269-277.
10. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonarybypass. J Thorac Cardiovasc Surg 1990;99:788-796.
11. De Smet AA, Joen MC, van Oeveren W, Roozendaal KJ, Harder MP, Eijsman L, Wildevuur CR. Increased anticoagulation during cardiopulmonarybypass by aprotinin. J Thorac Cardiovasc Surg 1990;100:520-577.
12. Landis RC, Asimakopoulos G, Poullis M, Haskard DO, Taylor KM. Theantithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001;72:2169-2175.
13. Day JR, Landis RC, Taylor KM. Aprotinin and the protease-activatedreceptor 1 thrombin receptor: antithrombosis, inflammation, and strokereduction. Semin Cardiothorac Vasc Anesth 2006;10:132-142.
14. Bulutcu FS, Ozbek U, Polat B, Yaļcin Y, Karaci AR, Bayindir O. Whichmay be effective to reduce blood loss after cardiac operations incyanotic children: tranexamic acid, aprotinin or a combination? PaediatrAnaesth 2005;15:41-46.
15. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM. A propensity score case-controlcomparison of aprotinin and tranexamic acid in high-transfusion-riskcardiac surgery. Transfusion 2006;46:327-338.